Monelisa 1ml

Monelisa® is a cross-linked hyaluronic acid dermal filler line developed by Genoss Co., Ltd. (South Korea). It is designed for facial wrinkle correction, lip enhancement, and soft to deep tissue volume restoration, depending on the specific Monelisa variant (Soft, Mild, Ultra, Hard). It is intended only for administration by qualified healthcare professionals trained in aesthetic injection procedures. Monelisa 1ml refers to a single pre-filled syringe (1ml HA filler) used in aesthetic medicine.

Packaging

• 1 × 1.0 mL pre-filled syringe
• Sterile single-use medical device
• Typically includes fine needles (27G–30G depending on variant)
• Lidocaine may be included in some versions for comfort

Composition

Based on manufacturer and distributor data:

• Cross-linked hyaluronic acid: ~20–24 mg/mL depending on variant
• BDDE cross-linking technology (ensures stability and longevity)
• Some versions include 0.3% lidocaine for pain reduction

Key characteristics:

• Non-animal origin hyaluronic acid
• Biocompatible and biodegradable gel
• Smooth gel consistency for controlled injection

Safety Information

Must only be used by qualified healthcare professionals.

Possible side effects:

• Swelling
• Bruising
• Redness
• Tenderness
• Temporary asymmetry or firmness

Rare risks:

• Vascular occlusion
• Infection
• Nodules or irregularities
• Allergic reaction

Contraindications:

• Active skin infection
• Allergy to hyaluronic acid or components
• Pregnancy or breastfeeding (unless medically approved)

Mechanism of Action

Monelisa works by:

• Restoring hydration and volume in dermal tissues
• Filling wrinkles and folds through physical gel support
• Binding water molecules to improve skin plumpness
• Providing structural support depending on viscosity level
• Gradually integrating into tissue over time

Product Features

• Cross-linked HA filler (~20–24 mg/mL range)
• Multiple formulations for different depths and effects
• Smooth injection properties
• Natural-looking correction of wrinkles and volume loss
• CE-certified in many markets (depending on variant)
• Reversible with hyaluronidase

Expected Results

Typical outcomes include:

• Smoother facial skin texture
• Improved lip fullness and shape
• Reduced appearance of wrinkles and folds
• Restored facial volume balance
• More youthful facial contours

Duration:

• Typically 6–12 months, depending on product type, area, and metabolism

Advantages

• Versatile filler line for multiple treatment depths
• Natural aesthetic results when properly used
• Good balance of elasticity and cohesion
• Suitable for lips and facial contouring
• Available in multiple density variants

Common Treatment Areas

A qualified professional may use Monelisa 1.0 mL for:

• Lips (volume + contour)
• Nasolabial folds
• Marionette lines
• Cheeks (mild to moderate volumization)
• Perioral lines (smoker’s lines)
• Under-eye and fine wrinkle correction (Soft type only)